GeneHarbor focuses on the development and manufacture of innovative biotech products, enzymes in particular, and enzymatic production of various highly value-added products. The company has developed a proprietary platform technology for production of various enzymes. The technology aims to reduce the cost & increase the life span of the enzymes. The Company also operates its own manufacturing facilities that industrially manufactures biochemicals of the highest standard.
Contact
Unit 507, 5/F, Bio-Informatics Centre, No. 2 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, Hong Kong
Tel: +852 2838 0306
Website: http://www.geneharbortech.com.hk/index.htm
Email: info@geneharbor.com.hk
Hong Kong is repositioning itself within the global innovation landscape, moving beyond its total market-driven model to take an industry policy oriented market-driven approach. Through Office for Attracting Strategic Enterprises…
Translating scientific breakthroughs into products that genuinely impact patients is more challenging than it has ever been. Only ten percent of drugs that enter clinical trials ever make it all…
Dr Jeremy Teoh of the Chinese University of Hong Kong leads a research programme spanning bladder cancer biology, surgical innovation, and translational science. From building what is believed to be…
When, in his 2023 policy address, Hong Kong Chief Executive John Lee announced the territory’s intention to conduct its own primary reviews of medicines, the initial industry reaction was mixed.…
After a rocky couple of years, Hong Kong has defied its sceptics and definitively bounced back. As Asia’s financial capital and the bridge between mainland China and international markets, the…
It is not unreasonable, at first glance, to ask why so many pharma multinationals have chosen to establish standalone affiliates in Hong Kong. After all, only 7.5 million people call…
Hong Kong – already Asia’s finance hub and an increasingly robust life science R&D destination – is placing huge bets on becoming the region’s prime location for developing, financing, and…
Hong Kong’s biotech capital market has completed one of the more dramatic reversals in recent years. After a brutal two-year drought in which valuations collapsed, liquidity evaporated, and companies were…
In 2026, regulation, policy, institutions, and expertise are aligning to ensure Hong Kong can be a player in an extremely competitive Asian clinical trials landscape. From real-world data studies to…
Amgen’s trajectory in Hong Kong reflects a broader shift underway across the territory’s healthcare landscape, where data-driven care and cross-sector collaboration are converging to accelerate access to innovation. Against the…
Xia JIN, co-founder & CEO of Hong Kong-based immunology biotech Immuno Cure, outlines the progress of its DNA vaccine platform, highlighting strong Phase I results for an HIV therapeutic vaccine…
A biochemistry PhD, Bin Li started out in Merck’s research labs before transitioning to Wall Street, where he was one of the few figures with the scientific, financial, and linguistic…
See our Cookie Privacy Policy Here
